Crescita Therapeutics Inc. Announces Final Consideration Payable to Shareholders Pursuant to Arrangement with ClinActiv
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that holders of the issued and outstanding common shares (the “Shares”) of the Company (each a “Shareholder”) will be entitled to receive $0.80 per Share (subject to any applicable withholdings) (the “Consideration”) under its previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all the Shares in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”).
The Company expects the Arrangement to be completed on June 3, 2026, subject to the satisfaction or waiver of all conditions to the Arrangement. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange (“TSX”) and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.
